Safety of ninety-minute daratumumab infusion.
Fiche publication
Date publication
août 2020
Journal
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CAILLOT Denis
Tous les auteurs :
Lombardi J, Boulin M, Devaux M, Cransac A, Pistre P, Pernot C, Payssot A, Lafon I, Caillot D, Gueneau P
Lien Pubmed
Résumé
Daratumumab is the first anti-CD38 monoclonal antibody of the class approved for recurrent and refractory multiple myeloma. Grade 3 and 4 Infusion-Related Reactions (IRRs) are frequent during the first and second infusions. Due to the risks associated with severe IRRs, daratumumab is systematically administered over a period of 3.5 hours.The main objective of this study was to evaluate the safety of a 90-minute daratumumab infusion from the third infusion.
Mots clés
Multiple myeloma, daratumumab, infusion related reaction, safety
Référence
J Oncol Pharm Pract. 2020 Aug 30;:1078155220951231